Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 31,800 shares, an increase of 10.8% from the December 31st total of 28,700 shares. Based on an average daily trading volume, of 31,700 shares, the days-to-cover ratio is currently 1.0 days.
Institutional Investors Weigh In On Alpha Tau Medical
Large investors have recently modified their holdings of the company. Walleye Capital LLC grew its position in shares of Alpha Tau Medical by 10.9% in the 2nd quarter. Walleye Capital LLC now owns 204,285 shares of the company's stock valued at $98,000 after buying an additional 20,096 shares during the last quarter. LMR Partners LLP boosted its stake in Alpha Tau Medical by 67.4% during the 3rd quarter. LMR Partners LLP now owns 112,986 shares of the company's stock worth $660,000 after purchasing an additional 45,500 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Alpha Tau Medical during the 1st quarter worth $42,000. Jane Street Group LLC acquired a new stake in Alpha Tau Medical during the 1st quarter worth $64,000. Finally, Walleye Trading LLC acquired a new stake in Alpha Tau Medical during the 1st quarter worth $65,000.
Get
Alpha Tau Medical alerts:
Alpha Tau Medical Price Performance
Alpha Tau Medical stock traded up $0.02 during mid-day trading on Tuesday, reaching $0.42. 3,980 shares of the company's stock were exchanged, compared to its average volume of 29,580. Alpha Tau Medical has a twelve month low of $0.18 and a twelve month high of $1.06. The company has a fifty day moving average of $0.31 and a 200-day moving average of $0.42.
Alpha Tau Medical Company Profile
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.
Featured Stories
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTSW)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
